IT202200007229A1 - COMPOSITION INCLUDING N-ACETYLCYSTEINE, VITAMIN D AND PREFERABLY GLUTATHIONE, ITS USES, AND RELATED PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS - Google Patents
COMPOSITION INCLUDING N-ACETYLCYSTEINE, VITAMIN D AND PREFERABLY GLUTATHIONE, ITS USES, AND RELATED PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS Download PDFInfo
- Publication number
- IT202200007229A1 IT202200007229A1 IT102022000007229A IT202200007229A IT202200007229A1 IT 202200007229 A1 IT202200007229 A1 IT 202200007229A1 IT 102022000007229 A IT102022000007229 A IT 102022000007229A IT 202200007229 A IT202200007229 A IT 202200007229A IT 202200007229 A1 IT202200007229 A1 IT 202200007229A1
- Authority
- IT
- Italy
- Prior art keywords
- acetylcysteine
- vitamin
- composition including
- nutraceutical compositions
- related pharmaceutical
- Prior art date
Links
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 title 2
- 239000000203 mixture Substances 0.000 title 2
- 108010024636 Glutathione Proteins 0.000 title 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 title 1
- 229960004308 acetylcysteine Drugs 0.000 title 1
- 229960003180 glutathione Drugs 0.000 title 1
- 239000002417 nutraceutical Substances 0.000 title 1
- 235000021436 nutraceutical agent Nutrition 0.000 title 1
- 229940088594 vitamin Drugs 0.000 title 1
- 229930003231 vitamin Natural products 0.000 title 1
- 235000013343 vitamin Nutrition 0.000 title 1
- 239000011782 vitamin Substances 0.000 title 1
- 150000003722 vitamin derivatives Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Biochemistry (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102022000007229A IT202200007229A1 (en) | 2022-04-12 | 2022-04-12 | COMPOSITION INCLUDING N-ACETYLCYSTEINE, VITAMIN D AND PREFERABLY GLUTATHIONE, ITS USES, AND RELATED PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS |
PCT/IB2023/053745 WO2023199244A1 (en) | 2022-04-12 | 2023-04-12 | Composition comprising n-acetylcysteine, vitamin d and preferably glutathione, uses thereof, and pharmaceutical and nutraceutical compositions thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102022000007229A IT202200007229A1 (en) | 2022-04-12 | 2022-04-12 | COMPOSITION INCLUDING N-ACETYLCYSTEINE, VITAMIN D AND PREFERABLY GLUTATHIONE, ITS USES, AND RELATED PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS |
Publications (1)
Publication Number | Publication Date |
---|---|
IT202200007229A1 true IT202200007229A1 (en) | 2023-10-12 |
Family
ID=82385403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IT102022000007229A IT202200007229A1 (en) | 2022-04-12 | 2022-04-12 | COMPOSITION INCLUDING N-ACETYLCYSTEINE, VITAMIN D AND PREFERABLY GLUTATHIONE, ITS USES, AND RELATED PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS |
Country Status (1)
Country | Link |
---|---|
IT (1) | IT202200007229A1 (en) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998029101A1 (en) * | 1996-12-31 | 1998-07-09 | Antioxidant Pharmaceuticals Corporation | Pharmaceutical preparations of glutathione and methods of administration thereof |
WO2003077900A1 (en) * | 2002-03-14 | 2003-09-25 | Prevention, L.L.C. | A unifying mechanism and methods to prevent cancer and neurodegenerative diseases |
US20070116779A1 (en) * | 2005-11-23 | 2007-05-24 | Elizabeth Mazzio | Comprehensive nutraceutical agent for treatment/ prevention of Parkinson's disease |
JP2010120916A (en) * | 2008-11-22 | 2010-06-03 | Rena Science:Kk | Agent for amelioration or treatment of mental disease and nervous system disease developing in relation to decrease in physiologically active monoamine in vivo |
US10105419B2 (en) * | 2015-02-13 | 2018-10-23 | Eastern Vision Limited | Dietary supplements and formulations |
WO2020053754A1 (en) | 2018-09-10 | 2020-03-19 | Uriach Italia S.R.L. | Composition comprising lipoic acid and vitamin d for the prevention and the treatment of neurodegenerative diseases and peripheral neuropathies |
US20200254073A1 (en) * | 2017-10-27 | 2020-08-13 | Beyond Barriers Therapeutics, Inc. | Enhanced delivery of antioxidants for treatment of central nervous system disorders involving oxidative stress |
-
2022
- 2022-04-12 IT IT102022000007229A patent/IT202200007229A1/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998029101A1 (en) * | 1996-12-31 | 1998-07-09 | Antioxidant Pharmaceuticals Corporation | Pharmaceutical preparations of glutathione and methods of administration thereof |
WO2003077900A1 (en) * | 2002-03-14 | 2003-09-25 | Prevention, L.L.C. | A unifying mechanism and methods to prevent cancer and neurodegenerative diseases |
US20070116779A1 (en) * | 2005-11-23 | 2007-05-24 | Elizabeth Mazzio | Comprehensive nutraceutical agent for treatment/ prevention of Parkinson's disease |
JP2010120916A (en) * | 2008-11-22 | 2010-06-03 | Rena Science:Kk | Agent for amelioration or treatment of mental disease and nervous system disease developing in relation to decrease in physiologically active monoamine in vivo |
US10105419B2 (en) * | 2015-02-13 | 2018-10-23 | Eastern Vision Limited | Dietary supplements and formulations |
US20200254073A1 (en) * | 2017-10-27 | 2020-08-13 | Beyond Barriers Therapeutics, Inc. | Enhanced delivery of antioxidants for treatment of central nervous system disorders involving oxidative stress |
WO2020053754A1 (en) | 2018-09-10 | 2020-03-19 | Uriach Italia S.R.L. | Composition comprising lipoic acid and vitamin d for the prevention and the treatment of neurodegenerative diseases and peripheral neuropathies |
Non-Patent Citations (5)
Title |
---|
ALI AMMAR ET AL: "Vitamin D exerts neuroprotection via SIRT1/nrf-2/ NF-kB signaling pathways against D-galactose-induced memory impairment in adult mice", NEUROCHEMISTRY INTERNATIONAL, ELSEVIER, AMSTERDAM, NL, vol. 142, 4 November 2020 (2020-11-04), XP086431488, ISSN: 0197-0186, [retrieved on 20201104], DOI: 10.1016/J.NEUINT.2020.104893 * |
FRANCESCA UBERTI ET AL: "Protective effects of 1 ? ,25-Dihydroxyvitamin D3 on cultured neural cells exposed to catalytic iron", PHYSIOLOGICAL REPORTS, vol. 4, no. 11, 1 June 2016 (2016-06-01), US, pages e12769, XP055586068, ISSN: 2051-817X, DOI: 10.14814/phy2.12769 * |
LEMON J A ET AL: "A dietary supplement abolishe age-related cognitive defcline in transgenic mice expressing elevated free radical processes", EXPERIMENTAL BIOLOGY AND MEDICINE, SAGE PUBLICATIONS LTD, GB, vol. 228, 1 January 2003 (2003-01-01), pages 800 - 810, XP002436865, ISSN: 1535-3702 * |
MOLINARI CMORSANUTO VGHIRLANDA S ET AL.: "Role of combined Lipoic acid and Vitamin D3 on Astrobytes as a way to prevent Brain aging by induced oxidative stress and Iron accumulation", OXID MED CELI LONGEV, 28 February 2019 (2019-02-28) |
ROSS ERIKA K ET AL: "Immunocal and preservation of glutathione as a novel neuroprotective strategy for degenerative disorders of the nervous system", RECENT PATENTS ON CNS DRUG DISCOVERY, BENTHAM SCIENCE PUBLISHERS LTD, NL, vol. 7, no. 3, 30 November 2012 (2012-11-30), pages 230 - 235, XP009501358, ISSN: 2212-3954 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017001847A1 (en) | A solid pharmaceutical dosage formulation | |
NO20081878L (en) | Diacylindazole derivatives as lipase and phospholipase inhibitors | |
ES2556585T3 (en) | Compositions comprising salbutamol sulfate | |
AR065246A1 (en) | COMPOSITIONS TO IMPROVE GASTROINTESTINAL ABSORPTION OF NUTRIENTS AND PHARMACOS | |
UY30215A1 (en) | CHROMANOL DERIVATIVES REPLACED, PROCEDURES FOR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND APPLICATIONS | |
BR112012006692A2 (en) | pharmaceutical composition comprising omega-3 fatty acid and a hydroxy derivative of a statin and methods of use thereof | |
BRPI0520669A2 (en) | pharmaceutical dosage that reduces the effect of food found for atorvastatin administration | |
AR051397A1 (en) | PHARMACEUTICAL COMPOSITION | |
AR060387A1 (en) | FOOD SUPPLEMENTS AND THEIR USES | |
CR10505A (en) | AMINOPIRAZOLOPIRIDINAS REPLACED AND ITS SALTS, ITS PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM | |
BRPI0617294B8 (en) | pharmaceutical composition in hydroalcoholic gel and use of testosterone | |
ATE511514T1 (en) | TYPE IV PHOSPHADIAZINE HCV POLYMERASE INHIBITORS | |
BR112016010875A8 (en) | USEFUL COMPOSITION FOR FEMALE FERTILITY PROMOTION | |
GT200800107A (en) | ORAL FORMULATIONS THAT INCLUDE TIGECICLINE | |
BRPI0814189A2 (en) | DOUBLE FILM RIBONUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND ITS USES, METHOD FOR INHIBITING PHOSPHYDYLINOSITOL 4-KINASE EXPRESSION, VECTOR AND USE OF A COMPOUND THAT SELECTIVELY INHIBITS PHOSPHTIDYLINOSITOL-4 PHASE. | |
NO20054945L (en) | Oral formulation of cladribine | |
ECSP10010167A (en) | NEW OPHTHALMIC COMPOSITIONS | |
DK3519416T3 (en) | CHROMAN, ISOCHROMAN AND DIHYDROISOBENZOFURAN DERIVATIVES AS MGLUR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS AND USES | |
NO20092763L (en) | Isosorbide mononitrate derivatives for the treatment of intestinal disorders | |
DE602006002303D1 (en) | Food composition for the prevention of fragility syndrome in seniors | |
IT202200007238A1 (en) | COMPOSITION INCLUDING N-ACETYLCYSTEINE, VITAMIN D AND PREFERABLY GLUTATHIONE, ITS USES, AND RELATED PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS | |
IT202200007229A1 (en) | COMPOSITION INCLUDING N-ACETYLCYSTEINE, VITAMIN D AND PREFERABLY GLUTATHIONE, ITS USES, AND RELATED PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS | |
EA201890202A1 (en) | NATURAL STYLBENES AS SWEETS OR AMPLIFIERS OF SWEETS | |
DK2094638T3 (en) | 2-aryl-2-fluoropropanoic acids and derivatives and pharmaceutical compositions containing them | |
IL304247A (en) | Spirocyclohexane derivatives, pharmaceutical compositions containing them and their uses as anti-apoptotic inhibitors |